LogicBio Therapeutics (OTCMKTS:LOGC) Reaches New 1-Year High – Should You Buy?

Shares of LogicBio Therapeutics, Inc. (OTCMKTS:LOGC) hit a new 52-week high during trading on Monday. The stock traded as high as $15.41 and last traded at $15.07, with a volume of 64811 shares changing hands. The stock had previously closed at $14.75.

LogicBio Therapeutics Price Performance

The company has a current ratio of 1.87, a quick ratio of 1.24 and a debt-to-equity ratio of 0.29. The business’s 50-day simple moving average is $11.93 and its two-hundred day simple moving average is $9.85. The firm has a market cap of $695.10 million, a price-to-earnings ratio of -20.82 and a beta of 2.11.

LogicBio Therapeutics (OTCMKTS:LOGC) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.10). The firm had revenue of $33.60 million for the quarter, compared to the consensus estimate of $33.60 million.

LogicBio Therapeutics Company Profile

LogicBio Therapeutics was a clinical-stage genetic medicine company focused on developing treatments for rare and serious genetic diseases. The company’s research centered on technologies designed to modify or deliver genetic material directly inside the body.

LogicBio’s principal technology platforms included GeneRide, an in vivo gene-insertion approach intended to enable long-term expression of therapeutic genes, and GeneWare, a genome-editing platform. Its lead investigational program, LB-001, was developed as a potential treatment for methylmalonic acidemia, a rare inherited metabolic disorder.

Founded in 2014 and headquartered in Cambridge, Massachusetts, LogicBio operated primarily as a biotechnology research and development company serving the rare-disease and genetic-medicine markets.